More sensitive. More specific. More complete immune repertoire analysis.
Lymphoid malignancies involve the clonal proliferation of one or more B or T cells. Every B and T cell expresses distinct receptors on its surface, which give rise to a vastly diverse immune repertoire. Using next-generation sequencing (NGS) technology, these unique receptor sequences can be used to assess clonality, detect rare clones, and measure somatic hypermutation (SHM).
NGS offers significant advantages over traditional approaches by providing sequence information, giving a more detailed view into repertoire (sub-clonal and intra-clonal) diversity, offering ultra-high sensitivity, and providing greater flexibility to multiplex.
Clonality and rare clone detection
NGS provides sequence-level resolution for clonality assessment, allowing you to detect expanded clones from poly-clonal samples with very high specificity. Integrated bioinformatic tools let you easily assess clonal lineage to better understand the relationship between two clones.
NGS offers a greater level of sensitivity when compared to traditional methods like flow cytometry. The ultralow limit of detection (LoD) of 10-6 (1 in 1,000,000 cells) enables you to detect extremely rare clones that traditional less-sensitive methods can miss.
Using proprietary Ion AmpliSeq technology, Oncomine immune repertoire assays can target multiple immune receptors in a single reaction, which can lead to increased positive clonality detection rates (>90%) and reduce the need for secondary testing.
Clonality and rare clone detection assays
- Oncomine BCR Pan-Clonality Assay—simultaneously sequence multiple receptor targets in a single reaction, including IGH, IgK, IgL rearrangements, as well as rearrangements containing C-intron (C-int) and kappa-deletion element (KDE)
- Oncomine BCR IGH SR Assay—assess clonality by targeting the CDR3 region of the IGH receptor
- Oncomine TCR Pan-Clonality Assay—sequence TCR beta and gamma targets in a single reaction
Somatic hypermutation analysis
Following V(D)J recombination in developing lymphocytes, the IGHV gene undergoes somatic hypermutation. During this process, a series of point mutations are introduced to help confer greater repertoire diversity and enable higher affinity for potential antigens.
The degree of somatic hypermutation is a key biomarker relevant for chronic lymphocytic leukemia (CLL) research. Long-amplicon NGS assays provide highly accurate IGHV SHM quantification, while enabling efficient batch sample processing and simplifying the workflow when compared to traditional Sanger sequencing methods.
Somatic hypermutation analysis assays
As with all Oncomine assays, the complete workflow is fully integrated for speed and convenience. Start with any common sample type and easily prepare libraries for sequencing on the Ion GeneStudio S5 System. Use either the Ion 530, Ion 540, or Ion 550 chip to meet your throughput requirements.
Powerful analysis from Ion Reporter software
- Interactive spectratyping plots make it easy to identify clonal expansion within the broader context of the repertoire
- Automated reporting features provide detailed information on each clone, including the CDR3 sequence, SHM frequency, clone frequency, and more
- Unique automated clonal lineage analysis enables the identification of subclones based on specific sequence characteristics
For Research Use Only. Not for use in diagnostic procedures.